SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ed Ajootian who wrote (1713)2/9/1999 7:49:00 PM
From: Epicenter  Read Replies (1) of 10280
 
Dear Ed:

This is what I could gather from the team of Tim Barberich, David Southwell and Paul Rubin today at the ML conference:

1) No timetable was specifically mentioned for Allegra interference case. TB said that he thought that most analysts had already factored this in in their estimates anyway.

2) NDA for Xopenex and final approval. TB mentioned "first half" of this year in his talk. In answer to the audience, final labelling still pending but should include better side effects profile etc., in his opinion.

3) Formeterol--Expected NDA--2000/2001 (DS)

4) Possible acquisition funded by stocks? Possible (DS)

5) Stock splits? Possible, has been a topic of discussion but nothing definitive (DS)

6) Unlikely to pursue Epilepsy, PD for now. Enough to do otherwise.

I also found out that they are heavily into setting up large combinatorial chemistry library for screening for NCE's for the present and the future. No specific NCE's were mentioned that can definitively go into IND in the near future.

Epicenter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News